Global CDMO Scope Inventia operates as a global CDMO for complex generics and novel products, offering end to end services from R&D to commercialization, with a client base spanning multiple markets. This positions it as a partner for big pharma and mid sized players seeking integrated development and scalable manufacturing to accelerate market entry.

End to End The company emphasizes end to end expansion capabilities, supporting clients entering emerging and regulated markets, enabling faster scale up and smoother regulatory filings, presenting opportunities to upsell from development to commercial manufacturing.

Compliance and Security A robust compliance and security posture, including ISO IEC 27001 alignment and international regulatory readiness, reduces client risk and supports audits, making Inventia attractive to global buyers prioritizing quality and data integrity.

Strategic Investment Backing Recent strategic investment by Platinum Equity signals potential for capital backing, capacity expansion, and broader collaboration opportunities, creating openings for new licensing deals, co development arrangements, or expanded supply agreements.

Global Footprint A strong regional footprint with a modern Ambernath facility offering scalable manufacturing in a regulatory compliant environment, coupled with global reach in numerous markets, supports reliable supply and potential diversification of product portfolios.